Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires $30,422.04 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,852 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was acquired at an average price of $6.27 per share, for a total transaction of $30,422.04. Following the acquisition, the chief executive officer directly owned 3,185,246 shares in the company, valued at $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

KindlyMD Price Performance

NASDAQ NAKA opened at $7.06 on Monday. The firm has a market capitalization of $126.37 million, a price-to-earnings ratio of -0.20 and a beta of 15.94. The company has a 50 day simple moving average of $4.54 and a 200-day simple moving average of $7.19. KindlyMD, Inc. has a 52-week low of $3.33 and a 52-week high of $422.40.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. The company had revenue of $35.87 million for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. On average, analysts predict that KindlyMD, Inc. will post -11.31 EPS for the current year.

Key KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Hedge Funds Weigh In On KindlyMD

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in KindlyMD in the fourth quarter valued at approximately $151,000. Invesco Ltd. acquired a new position in shares of KindlyMD during the 4th quarter worth $211,000. NewEdge Advisors LLC acquired a new position in shares of KindlyMD during the 4th quarter worth $316,000. Charles Schwab Investment Management Inc. bought a new position in shares of KindlyMD during the 4th quarter valued at $727,000. Finally, State Street Corp bought a new position in shares of KindlyMD during the 4th quarter valued at $593,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on NAKA shares. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Finally, TD Cowen lifted their price objective on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.33.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.